| BCBS Federal Medical & Drug | 2.04.102 Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.111 Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.125 Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung Cancer | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.128 Genetic Testing for Fanconi Anemia | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.131 Pharmacogenetic Testing for Pain Management | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.136 Nutrient/Nutritional Panel Testing | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.137 Genetic Testing for Neurofibromatosis | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.141 Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.147 Next-Generation Sequencing for the Assessment of Measurable Residual Disease | 2026-03-01 |